Wird geladen...
Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
PURPOSE: The usual first-line strategy of wild-type EGFR (wtEGFR) non-small cell lung cancer (NSCLC) remains cisplatin-based chemotherapy. However, cisplatin often loses effectiveness because most tumors acquire drug resistance over time. As EGFR is the most important pro-survival/proliferation sign...
Gespeichert in:
| Veröffentlicht in: | J Cancer Res Clin Oncol |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Springer Berlin Heidelberg
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7185832/ https://ncbi.nlm.nih.gov/pubmed/32342201 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-020-03228-4 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|